Not Yet RecruitingNot Applicable

Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation

Denmark50 participantsStarted 2026-01

Plain-language summary

The investigators aim to assess the risk of bleeding and thrombo-embolic complications as well as benefit and harm of blood product transfusion and anticoagulation therapy in adult ICU patients with COVID-19 supported with V-V ECMO

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Adults * Polymerase chain reaction (PCR) verified COVID-19 infection * Supported with V-V ECMO in this center Exclusion criteria: \- none

What they're measuring

Bleeding events

Timeframe: 90 days

Trial details

NCT IDNCT07352072

SponsorRigshospitalet, Denmark

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-06

Contact for this trial

Andreas Bender Johsson, MD

004535458947 andreas.bender.jonsson@regionh.dk

View on ClinicalTrials.gov More VV ECMO trials